Vantage Consulting Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-488	Closed	-$229K	–	176
2024 Q2	$229K	Sell	488 -88	-15%	-$38.2K	0.17%	148
2024 Q1	$241K	Sell	576 -90	-14%	-$38K	0.15%	139
2023 Q4	$271K	Sell	666 -12	-2%	-$4.43K	0.18%	96
2023 Q3	$236K	Sell	678 -12	-2%	-$4.2K	0.16%	128
2023 Q2	$243K	Sell	690 -145	-17%	-$48.9K	0.14%	140
2023 Q1	$263K	Buy	835 +63	+8%	+$18.9K	0.15%	126
2022 Q4	$223K	Sell	772 -103	-12%	-$31.4K	0.13%	166
2022 Q3	$253K	Sell	875 -70	-7%	-$20.1K	0.15%	106
2022 Q2	$266K	Sell	945 -27	-3%	-$7.23K	0.15%	99
2022 Q1	$254K	Sell	972 -280	-22%	-$66.5K	0.1%	132
2021 Q4	$275K	Sell	1,252 -40	-3%	-$7.78K	0.07%	145
2021 Q3	$234K	Buy	1,292 +115	+10%	+$22.5K	0.05%	158
2021 Q2	$237K	Buy	+1,177	New	+$246K	0.04%	151
2021 Q1	–	Sell	-322	Closed	-$76K	–	1546
2020 Q4	$76K	Buy	+322	New	+$73.9K	0.01%	271